Physician profile
James E Palen
NPI 1114973161
$4,445.54
in general payments reported to CMS, 2019-2025
43 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $504 · 2021: $941 · 2022: $812 · 2023: $762 · 2024: $526 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,727.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,157.63 | 2020-2025 | |
| Lilly USA, LLC | $427.74 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $280.90 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $242.57 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $221.26 | 2019-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $187.71 | 2019-2024 | Xarelto |
| Eisai INC. | $166.40 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $152.16 | 2020-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $152.13 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $149.10 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.67 | 2019-2025 | Jardiance |
| Axsome Therapeutics, INC. | $103.05 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $92.20 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.28 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $75.76 | 2019-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Palen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.